SAVA
Cassava Sciences, Inc.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.09
P/S
0.00
EV/EBITDA
0.15
DCF Value
$1.15
FCF Yield
-109.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-97.9%
ROA
-76.9%
ROIC
-128.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-12.5M | $-0.26 |
| FY 2025 | $0.00 | $-91.0M | $-1.88 |
| Q3 2025 | $0.00 | $-10.8M | $-0.22 |
| Q2 2025 | $0.00 | $-44.2M | $-0.92 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.84
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.